This company appears to be developing medical technology or services, though specific details are not yet available on their site. They are currently preparing to launch their official online presence. Further information will be provided upon the site's completion.
Funding
$1.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Mitral and tricuspid valve regurgitation often require invasive surgical procedures. Current treatment options may not adequately preserve normal cardiac motion, potentially leading to suboptimal patient outcomes.
Solution
Opus Medical Therapies is developing a transseptal transcatheter mitral valve replacement (TMVR) device that utilizes a proprietary anchoring platform to securely position intracardiac implants. The Opus TMVR is designed to treat both primary and secondary mitral regurgitation, as well as tricuspid valve regurgitation. The device aims to provide a less invasive treatment option while maintaining normal cardiac function. The anchoring platform is designed to be versatile and adaptable for securing various intracardiac implants.
Target Audience
The primary target audience includes interventional cardiologists and cardiac surgeons treating patients with mitral and tricuspid valve regurgitation.
Features
- Proprietary universal anchoring platform for stable intracardiac implant fixation
- Transseptal delivery approach for less invasive valve replacement
- Designed to preserve normal cardiac motion
- Suitable for both mitral and tricuspid valve regurgitation